Translate

Search

Saturday, May 5, 2012

Publishing And Digital And Electronic Rights

The following publishing industry article addresses some of the legal issues arising for publishing lawyers, entertainment attorneys, authors, and others as a result of the prevalence of e-mail, the Internet, and so-called "digital" and "electronic publishing". As usual, publishing law generally and the law of the digital right and electronic right specifically, governing these commercial activities, has been slow to catch up to the activity itself. Yet most of the publishing industry "gray areas" can be resolved by imposing old common-sense interpretations upon new publishing lawyer and entertainment lawyer industry constructs, including the digital right and electronic right, and others. And if after reviewing this article you believe you have a non-jargonized handle on the distinction between "digital right" and "electronic right" in the publishing context, then I look forward to hearing from you and reading your article, too.

1. "Electronic Right[s]" And "Digital Right[s]" Are Not Self-Defining.

All publishing lawyers, entertainment attorneys, authors, and others must be very careful about the use of jargon - publishing industry jargon, or otherwise. Electronic and digital publishing is a recent phenomenon. Although as a publishing lawyer and entertainment attorney and unlike some others, I tend to use the phrase "electronic right" or even "digital right" in the singular number, there probably tends to be no single consensus as to what constitutes and collectively comprises the singular "electronic right" or "digital right". There has not been sufficient time for the publishing, media, or entertainment industries to fully crystallize accurate and complete definitions of phrases like "electronic publishing", "web publishing", "electronic right[s]", "e-rights", "digital rights", or "first electronic rights".

These phrases are therefore usually just assumed or, worse yet, just plain fudged. Anyone who suggests that these phrases alone are already self-defining, would be wrong.

Accordingly, anyone, including a publishing lawyer or paralegal representing a book publisher or entertainment lawyer representing a studio or producer, who says that an author should do - or not do - something in the realm of the "electronic right" or "digital right" because it is "industry-standard", should automatically be treated with suspicion and skepticism.

The fact of the matter is, this is a great era for authors as well as author-side publishing lawyers and entertainment attorneys, and they should seize the moment. The fact that "industry-standard" definitions of the electronic right and digital right have yet to fully crystallize, (if indeed they ever do), means that authors and author-side publishing lawyers and entertainment attorneys can take advantage of this moment in history.

Of course, authors can also be taken advantage of, too - particularly those not represented by a publishing lawyer or entertainment attorney. There is a long and unfortunate history of that happening, well prior to the advent of the electronic right and digital right. It has probably happened since the days of the Gutenberg Press.

Every author should be represented by a publishing lawyer, entertainment attorney, or other counsel before signing any publishing or other agreement, provided that their own economic resources will allow it. (But I am admittedly biased in that regard). Part of the publishing lawyer and entertainment attorney's function in representing the author, is to tease apart the different strands that collectively comprise the electronic right or digital right. This must be done with updated reference to current technology. If your advisor on this point is instead a family member with a Smith-Corona cartridge typewriter or a Commodore PET, rather than an entertainment attorney or publishing lawyer, then it may be time to seek a new advisor.

Even authors who cannot afford publishing lawyer or entertainment attorney counsel, however, should avoid agreeing in writing to give broad contractual grants to publishers of "electronic publishing" - or the "electronic right", or "electronic rights" or "digital rights", or the "digital right". Rather, in the words of "Tears For Fears", the author and author counsel had "better break it down again". Before agreeing to grant anyone the author's "digital right: or "electronic right", or any elements thereof, the author and his or her publishing lawyer and entertainment attorney need to make a list of all the possible and manifold electronic ways that the written work could be disseminated, exploited, or digitally or electronically otherwise used. Notice that the author's list will likely vary, month to month, given the fast pace of technological advancements. For example, these kinds of questions can be considered by the author and publishing lawyer and entertainment attorney alike:

Electronic Digital Right Question #1, Asked By The Publishing Lawyer/Entertainment Attorney To The Author: Can the work be published in whole or in part on the Internet? In the context of an "e-zine"? Otherwise? If so, how? For what purpose? Free to the reader? For a charge to the reader?

Electronic Digital Right Question #2, Asked By The Publishing Lawyer/Entertainment Attorney To The Author: Can the work be disseminated through private e-mail lists or "listservs"? Free to the reader? For a charge to the reader?

Electronic Digital Right Question #3, Asked By The Publishing Lawyer/Entertainment Attorney To The Author: Can the work be distributed on CD-Rom? By whom? In what manner and context?

Electronic Digital Right Question #4, Asked By The Publishing Lawyer/Entertainment Attorney To The Author: To what extent does the author, himself or herself, wish to self-publish this work, either before or after granting any electronic right or any individual "electronic publishing" rights therein to someone else? Will such self-publication occur on or through the author's website? Otherwise?

Electronic Digital Right Question #5, Asked By The Publishing Lawyer/Entertainment Attorney To The Author: Even if the author does not self-publish, to what extent does the author wish to be able to use and disseminate this writing for his or her own portfolio, publicity, or self-marketing purposes, and perhaps disseminate that same writing (or excerpts thereof) electronically? Should that be deemed invasive of, or competitive with, the electronic right as otherwise contractually and collectively constituted?

The above list is illustrative but not exhaustive. Any author and any publishing lawyer and entertainment attorney will likely think of other elements of the electronic and digital right and other uses as well. The number of possible uses and complexities of the electronic right[s] and digital right[s] definitions will increase as technology advances. In addition, different authors will have different responses to the publishing lawyer and entertainment attorney, to each of the carefully-itemized questions. Moreover, the same author may be concerned with the electronic right in the context of one of his/her works, but may not care so much in the context of a second and different work not as susceptible to digital right exploitation. Therefore, the author must self-examine on these types of electronic and digital right questions before responding to the author's publishing lawyer or entertainment attorney and then entering into each individual deal. Only by doing so can the author avoid the pitfalls and perils of relying upon lingo, and relying upon someone else to dictate to them what is the electronic right or digital right "industry standard". As the publishing lawyer and entertainment attorney should opine, "There is no such thing as 'industry standard' in the context of a bilaterally-negotiated contract. The only standard that you the author should be worried about is the motivational 'standard' known as: 'if you don't ask, you don't get'".

Finally, the author should be aware that while the electronic right, digital right, and components thereof can be expressly granted, they can also be expressly reserved to the author, by a mere stroke of the pen or keystroke made by the publishing lawyer or entertainment attorney. For example, if an author wants to expressly reserve the "portfolio uses" mentioned in Electronic Digital Right Question #5 above, then the author should ask his or her publishing lawyer or entertainment attorney to clearly recite this reservation of the author portfolio electronic/digital right in the contract, and leave nothing to chance. In addition, if the author has some negotiating leverage, the author, through the publishing lawyer or entertainment attorney, may be able to negotiate the "safety net" of a "savings clause" which provides words to the effect that: "all rights not expressly granted to publisher, be it an electronic right or digital right or otherwise, are specifically reserved to author for his/her sole use and benefit". That way, the "default provision" of the contract may automatically capture un-granted rights including any electronic or digital right for the author's later use. This publishing lawyer and entertainment attorney drafting technique has likely saved empires in the past.

2. Publishers and Entertainment Companies Are Revising Their Boilerplate Agreements, As We Speak, In An Effort To Secure The Electronic Right[s].

It is well-known and should come as no surprise that right now, as we speak, publishers and their in-house and outside counsel publishing lawyers and entertainment attorneys are furiously re-drafting their boilerplate contracts to more thoroughly capture the digital and electronic right - that is, all of an author's digital and electronic rights. The typical publishing agreement drafted by a company-side publishing lawyer or entertainment attorney will recite a broad grant of rights, then followed by a whole laundry-list of "including but not limited to" examples. If the author receives such an onerous-looking rights passage from a publisher or the publisher's publishing lawyer or entertainment attorney, the author should not be intimidated. Rather, the author should look at it as an opportunity to make some money and have some fun. The author can first compare the list suggested in Electronic Digital Right Questions #1 through #5 above, to the publisher's own laundry-list and the author's own imagination. Then, the author can decide which if any of the separate digital or electronic rights the author wants to fight to keep for himself or herself.

If the publisher tells the author to blindly subscribe to their entire digital or electronic right[s] clause (or clauses), then the author still has the ultimate leverage, which is to walk away from the proposed deal prior to signature. Of course, this strategic approach wouldn't be advisable in most cases - unless perhaps if the author has other written offers from other publishers already on the table. However, an author shouldn't be forced by any publisher or any company-side publishing lawyer or entertainment attorney to sign away the electronic right, digital right, or any other rights that the author would rather keep - particularly rights which the author never specifically intended to shop to the publisher in the first instance.

The author should keep in mind the psychology and motivations of the publishers and their publishing lawyer and entertainment attorney counsel when doing all of this. A Vice-President (or above) at the publishing company probably woke up one recent morning, and realized that his/her company lost a great deal of money on a particular project by not taking a prospective license or assignment of an electronic right or digital right from another author. The VP probably then blamed the company's in-house legal department publishing lawyers or entertainment attorneys, who in turn started frantically re-drafting the company boilerplate to assuage the angry publishing executive and thereby keep their jobs. When in-house publishing lawyers, entertainment attorneys, or others engage in this type of practice (some may call it "drafting from fear"), they tend to go overboard.

Accordingly, what you will probably see is a proverbial "kitchen sink" electronic right clause which has been newly-drafted and perhaps even insufficiently reviewed by the company-side publishing lawyers and entertainment attorneys, internally and themselves - wherein the publisher will ask the author for every possible electronic and digital right and every other thing, including (without limitation) the kitchen sink. The only response to such a broad-band electronic right or digital right clause is a careful, deliberate, and methodical reply.

Using the approach outlined in Section #1 above, the author and the author's publishing lawyer or entertainment attorney counsel must separately tease apart each use and component of the electronic right and digital right that the publisher's broad-band clause might otherwise capture, and then opine to the publisher a "yes" or a "no" on each line-item. In other words, the author, through his or her publishing lawyer or entertainment attorney, should exercise his or her line-item veto. It's the author's writing that we are talking about, after all. The author should be the one to convert the singular "electronic right" or "digital right" into the laundry-list of electronic rights. That's why I use the singular number when referring to "electronic right" or "digital right" - I like to let the technologically-advanced author have all the fun making the list. That way, too, the author can tell me what he or she thinks the phrases actually mean, and what the difference between the two meanings really is, if anything.

Next, a few words in defense of the publishers and the publishing lawyers that work for them!

Up to now, this article discussed how phrases like the "digital right" or "electronic right" should not be assumed to be self-defining, even by and between publishing lawyers and entertainment attorneys, and how it is incumbent upon authors to reserve needed rights like the digital right or the electronic right to themselves in the context of a publishing deal. Next up, let's examine concepts such as the digital right or electronic right from the perspective of the publishing lawyer and entertainment attorney, and the standpoint of fairness - who between author and publisher should in fact hold on to the digital right and electronic right, once and assuming that they are first properly defined?

3. Yes, Digital Right And Electronic Right Uses Do Compete With Traditional Book Publishing Uses.

A publishing lawyer or entertainment attorney may be called upon to handle an author-side deal. A publishing lawyer or entertainment attorney may also be called upon to handle, under different factual circumstances, a publisher-side deal. So, now, a few words in defense of publishers, I suppose.

There is a perception in the author and Internet communities that publishers should not be taking broad grants of the digital right or electronic right from authors, since "digital rights and electronic rights do not compete or interfere with traditional book publishing and other media rights".

Not true. Not anymore. For proof of that fact, ask a few veteran news desk editors whether or not they followed, or were otherwise concerned about, what appeared on the Drudge Report during the Clinton administration. Ask the CFO's or in-house publishing lawyers of a few traditional encyclopedia companies how they feel about Wikipedia.

Incidentally, although as a publishing lawyer and entertainment attorney and unlike some others, I tend to use the phrase "electronic right" or even "digital right" in the singular number, there probably tends to be no single consensus as to what constitutes and collectively comprises the singular "electronic right" or "digital right". There has not been sufficient time for the publishing, media, or entertainment industries to fully crystallize accurate and complete definitions of phrases like "electronic publishing", "web publishing", "electronic right[s]", "e-rights", "digital right[s]", or "first electronic rights".

Nevertheless, electronic media and specifically the digital right and electronic right, have already changed our history. You can be sure that they will have some effect, at a minimum, on most author's individual publishing deals henceforth, and will be the fodder of publishing lawyer and entertainment attorney discussion for years to come. The fact is, electronic uses inherent in the digital right and the electronic right already do compete with older, more traditional uses - particularly because digital and electronic uses are cheaper and faster to deploy, and can potentially reach millions of users in less than, as Jackson Browne might say, the blink of an eye.

Commerce is increasingly relying upon the Internet and other electronic phenomena, and the linchpin of this reliance is the digital right and electronic right. After all, you are reading this article, and ostensibly gleaning some information or material from it. The Web, for example, has already put a sizable dent in dictionary and encyclopedia sales, and anyone who tells you otherwise is probably an employee in a dictionary or encyclopedia publishing company or publishing lawyer in-houser in denial of the digital and electronic right, trying to protect his/her stock options. As the recent and well-known Stephen King pilot program will attest, fiction is the next subject matter area to be affected. Many of us book lovers including publishing lawyers and entertainment attorneys don't like to think about it, but bound hard-copy books may soon become the sole province of book collectors and publishing lawyer vanity bookcases alone. The vast majority of book readers, however, may so wholly embrace the digital right and electronic right that they soon even lose the patience to wait for their "amazon.com" mailed shipment.

Very few people who work in the publishing, media, and entertainment industries, including as amongst fair-minded publishing lawyers and entertainment attorneys, should dispute that electronic uses inherent in the digital right and electronic right can easily cannibalize the older and more traditional forms and formats. This cannibalization will only increase, not decrease, as time goes on. Again, the author should put himself/herself in the mind-set of the publisher or its in-house publishing lawyer, when having this digital right/electronic right argument with the publisher or publishing lawyer. The publisher otherwise may want to invest marketing and personnel support in the author's work, and perhaps even pay the author an advance for the writing. In their view, though, the publisher's publishing lawyer or entertainment attorney argues, why should they do so, and not also capture the author's digital right or electronic right?

The last thing that the publisher or its publishing lawyer or entertainment attorney wants to do is to pay the author - and then discover that the author has "scooped" the publication with the author-reserved digital right or electronic right, stolen the publisher's proverbial fire, and undermined the publisher's investment in the author and the writing. The concern of the publisher and the book company's in-house publishing lawyer or outside entertainment attorney is rational and valid. If the publisher allows the author to potentially undercut the book by exploiting author's reserved digital right or electronic right, then the publisher is threatening the publisher's own investment in the author and in the written work. (And on some subliminal level at least, the company's in-house publishing lawyer also knows that this could come out of his or her future comp).

Compromises are available. One traditional compromise effected between publishing lawyers or entertainment attorneys is a so-called "hold-back" on the digital right or electronic right, whereby the author promises not to use or license-out any author-reserved digital right or electronic right for a certain period of time following publication. The author will need some leverage to get a publisher to agree to such a compromise, though. And a publishing lawyer or entertainment attorney should draft the clause - the author's publishing lawyer or entertainment attorney, not the publisher's counsel!

An author may think that small "portfolio" uses (e.g., tucked inside greeting cards, on an author's personal web site, etc.) are so minor, that they will never compete with publishing rights granted for the same work, and may tell the publisher or the company's publishing lawyer or entertainment attorney as much. The greeting card example does seem innocuous enough, but the publisher and its entertainment or publishing lawyer will likely not agree with the author regarding the author's personal web site. It is the electronic right or the digital right that really scares publishers and their publishing lawyers and entertainment attorneys, and is perceived as threatening to their long-term investment in the author and his or her work.

The distinction to be made here is between hard-copy portfolio uses, and digital right or electronic right "portfolio uses". The fact is that computer-uploaded text is so easy and quick to transmit, receive, and read. The posted content's popularity could also spread like digital wildfire, so quickly - for example, if a company hyper-links to the author's site, or if "Yahoo" bumps the author's site up in their search-engine pecking-order. Many successes have already been made by virtue of digital right and electronic right self-publishing, and more will follow. Traditional (book) publishers and their publishing lawyers and entertainment attorneys already realize this fact. Accordingly, traditional book publishers and their counsel also realize that once they acknowledge an author's reservation of a "self-promotion" digital right or electronic right, they risk losing control of a potential wildfire dissemination method. Again, this would put the publisher's investment at risk - but smart business people and companies and the publishing lawyers and entertainment attorneys that represent them, don't put their own investments at risk.

4. The Party To The Contract That Has The Better And More Immediate Means and Resources To Exploit The Electronic Rights, Should Be The One Who Takes The Electronic Rights.

Here is the final point. If a contracting party has no means and resources to exploit a digital right or electronic right or a given bundle of them, then that same party has no business taking (or reserving to themselves) those same digital or electronic rights by contract or even negotiating such a position by and between publishing lawyers or entertainment attorneys. To analogize, if I am a screenwriter who options or sells my script to the Acme Production Company, LLC, through an entertainment lawyer, how should I react if Acme asks me to specifically and contractually grant them "theme park rights" in my literary property in the negotiation between the entertainment attorneys? (Don't laugh - this practice is now very prevalent in film and entertainment deals).

Well, if Acme doesn't have its own theme park, I (or my entertainment attorney) now have a powerful argument for reserving the theme park rights to myself instead. "Hey, Acme", I (or my entertainment attorney) say, "... how do you have the unmitigated gall to ask me for my theme park rights, when you don't even have the ability to exploit or use them yourself? You don't even have a theme park!" I (or my entertainment attorney) then make it clear to Acme that I don't intend to be giving them any trophies that they can put on a shelf to collect proverbial dust.

The same argument can work in the publishing context, particularly as argued between publishing lawyers and entertainment attorneys, regarding the digital right or the electronic right. The author can proverbially cross-examine the publisher (or try to cross-examine the company's publishing lawyer or entertainment attorney) as to what successful past uses they have made of other author's digital rights or electronic rights across multiple books. The company President may fudge the answer, but the publishing lawyer or entertainment attorney representing the publisher must answer truthfully. (One good reason to negotiate through counsel).

If the true answer to the question is "none", then the author can use the "trophy" argument stated above. If the true answer is, alternatively, "some", then the author has a negotiating opportunity to compel the publisher and its publishing lawyer and entertainment attorney to contractually commit to digitally and electronically publish the author's work, too. The author can argue: "I won't grant you the digital right or electronic right unless you, publisher, contractually commit in advance as to how specifically you will exploit them, and how much money you will spend in their development and marketing". The author or the author's publishing lawyer or entertainment attorney can then carve those electronic right and digital right commitments right directly into the contract, if the author has the leverage to do so. Again, one should not try this at home - but instead use a publishing lawyer or entertainment attorney.

Needless to say, once the author makes the publisher commit, presumably through publishing lawyer or entertainment attorney counsel, to a development budget or other marketing or "release" commitment for the digital right or the electronic right, then both the author and the publisher might thereby also have some basis for numerical valuation of the rights themselves. And, it is an entirely reasonable argument for an author or author's publishing lawyer or entertainment attorney to say to a publisher that: "I will license/sell you the following listed digital right[s] or electronic right[s] if you pay me the following additional amounts for them:_____________________. And in the blank space, the rights can be listed like menu options as they have been broken out in Item #1 above, each to which separate dollar values - that is, price-tags - are now assigned.

Click the "Articles" button at: http://www.tormey.org/art.htm to return to the main Articles page.

ATTORNEY ADVERTISEMENT

This article is not intended to, and does not constitute, legal advice with respect to your particular situation and fact pattern. Do secure counsel promptly, if you see any legal issue looming on the horizon which may affect your career or your rights. What applies in one context, may not apply to the next one. Make sure that you seek individualized legal advice as to any important matter pertaining to your career or your rights generally.

Publishing And Digital And Electronic Rights
© John J. Tormey III, PLLC. All Rights Reserved.

My law practice as a publishing lawyer and entertainment attorney includes the drafting, editing, negotiation, and closure of agreements including digital and electronic rights matters as they may arise therein, as well as in the fields of music, film, television, Internet, and other media and art forms. If you have questions about legal issues which affect your career, and require representation, please contact me:

Law Office of John J. Tormey III, Esq.
John J. Tormey III, PLLC
217 East 86th Street, PMB 221
New York, NY 10028
(212) 410-4142 (phone)
(212) 410-2380 (fax)
e-mail: brightline@att.net
http://www.tormey.net
ATTORNEY ADVERTISEMENT

Article Source: EzineArticles.com

Wednesday, January 4, 2012

Fwd: | 12.12.11 | Symmetry to snap up J&J instruments biz for $165M



-------- Original Message --------
Subject: | 12.12.11 | Symmetry to snap up J&J instruments biz for $165M
Date: Mon, 12 Dec 2011 11:57:49 -0500 (EST)
From: FierceMedicalDevices <editors@fiercemedicaldevices.com>
Reply-To: editors@fiercemedicaldevices.com
To: nbrauchitsch@yahoo.com


December 12, 2011

Subscribe | Website | Jobs | Mobile
Refer FierceMedicalDevices to a Colleague

This week's sponsor:
Asuragen
Biotech Primer

Editor's corner:
Ebook download: Companion diagnostics--the future of medicine

Today's Top Stories:
1. Symmetry to buy instruments biz of J&J unit
2. STERIS, Toshiba team up on hybrid suites
3. Tissue Regenix to raise $39M
4. Bluegrass sees enrollment in Surfacer trial
5. Stryker to shut Gaymar facilities, cut 160 jobs

Spotlight:
Boston Sci introduces Charger catheter

Also Noted:
Boston Sci fights IRS notice on tax; Ex-Olympus CEO looks to reform Japanese boardrooms; Much more...

News From The Fierce Network:
1. Bayer bracing for profit-margin drop
2. Pfizer seeks 2nd chance for Mylotarg
3. Pharma hacker gets jail sentence in NJ


Webinar: Next Gen Sequencing from FFPE Samples
December 14, 2 pm ET / 11am PT
LAST CHANCE TO REGISTER!

Next generation sequencing (NGS) technologies hold enormous promise to advance personalized medicine applications in cancer. However, challenging real-world tumor specimens have not been carefully addressed by NGS procedures. We developed two complementary and scalable PCR-based target enrichment methods for amplifying dozens to thousands of cancer gene loci. Register today.


Editor's Corner

Ebook download: Companion diagnostics--the future of medicine

By Tracy Staton Comment | Forward | Twitter | Facebook | LinkedIn

About two weeks ago, the biggest-selling drug of all time fell off patent. The flurry of news coverage wasn't just about Lipitor and Pfizer's future without that $10 billion-plus in annual sales. It was the symbolic end of an era, a sort of mourning-the-passing of a time when Big Pharma stocks flew high and companies were hiring by the hundreds in the U.S. and Europe rather than China.

Of course, some pundits pointed out that mass-market blockbusters aren't completely passé. But much of the talk focused on another approach to the drug business: treatments for small populations. In some cases, those patients are easy to spot; they're the ones with rare, debilitating diseases, and payers are willing to spend tens of thousands--even hundreds of thousands--on their treatment.

Others aren't so obvious. They can't be picked out of a lineup without a diagnostic test. Many can't even be identified that way yet, because the biomarkers that distinguish their disease haven't been found. But these patients promise a way forward for drugmakers that can find those markers and treat the patients who have them--and the diagnostics companies that can develop tests to identify those patients.

Consider this: Just as Pfizer was preparing to turn the page on Lipitor, it won approval for a lung cancer drug that works in less than 5% of patients. Xalkori fights the disease in patients with a variant of the ALK gene. It's priced at $9,600 per month, or $115,200 per year of treatment. Analysts expect it to peak at an enviable $2.5 billion in annual sales.

On the same day that Pfizer won the FDA's approval for Xalkori, Abbott Laboratories got the OK for a diagnostic test that identifies appropriate patients. The diagnostic-and-drug team, and its tandem approval, are just the sort of developments the FDA says it wants to encourage. But for a variety of reasons--from regulatory snarls to cultural stumbling blocks--the Xalkori success is more of an exception than a rule. That's changing, thanks to some forward-thinking companies, advocacy groups, payers, investors, and, yes, even regulators.

In a new ebook, we've taken a look at the development of targeted drugs and companion diagnostics, from the successful projects to the not-so-successful, and at the obstacles that remain. What's being done to overcome them? What can companies themselves do? And what's the potential payoff of all that work? We invite you all to check it out.

Click here to download the free ebook on companion diagnostics. - Tracy Staton (twitter | email)

Publishers Note: This complimentary e-book PDF download made possible by our sponsor Myraqa. And watch this space on Wednesday for Kindle, Nook, and iBooks optimized versions. - Arsalan Arif, Publisher (twitter | email)

Read more about: companion diagnostics

Webinars

> Drug Development: An Overview of the Regulated Clinical Trials Process Used to Bring a New Drug to Market - Dec 13, 1 pm ET/10 am PT

Events

> ExL Pharma's Digital Marketing for Medical Devices: Europe - 12-13 December 2011 - Kempinski Bristol ~ Berlin, Germany
> Online GMP Courses Priced as Low as $75 for Individual Learners

Marketplace

> Digital Health Technology: A Guide to Medtech's Biggest New Player

Jobs

> Director, Reagent Manufacturing & Operations - San Francisco, CA - Fluidigm
> Director of Operations at Pharm-Olam International
> Manager, Strategic Forecasting & Analytics Job – NJ – Celgene Corporation
> Sr. Product Manager – NJ – Celgene Corporation
> Business Analyst - Gaithersburg, MD - MedImmune
> IT Infrastructure Portfolio & Planning Analyst - Gaithersburg, MD - MedImmune
> Senior Manager, Information Architect - Gaithersburg, MD - MedImmune
> Systems Analyst - Gaithersburg, MD - MedImmune
> Data Center Fac.Engineer– Gaithersburg, MD - MedImmune

Drug Development: An Overview of the Regulated Clinical Trials Process Used to Bring a New Drug to Market
Dec 13, 1 pm ET/10 am PT

Join us for a one-hour overview of the regulated clinical trials process used to bring a new drug to market.
Topics include: Clinical Trial Considerations, Phase 1, Phase 2a and 2b, Phase 3 and 3b, Phase 4, Pharmacoeconomics, Risk Management Plan and more. Register today.

Today's Top Stories

1. Symmetry to buy instruments biz of J&J unit

By Liz Jones Hollis Comment | Forward | < a href="http://links.mkt1985.com/ctt?kn=2&ms=MzgxNTI0NwS2&r=MjM2NzI3MjAzMjcS1&b=0&j=MTE4MTExMDIwS0&mt=1&rt=0" name="api_addthis_com_oexchange_3iQHqgzIwgVQvMomz558Hg" >Twitter | Facebook | LinkedIn

Symmetry Medical ($SMA) has agreed to buy the surgical instruments business of Codman & Shurtleff, a unit of Johnson & Johnson ($JNJ), for $165 million in cash.

The transaction includes Codman's reusable stainless steel and titanium surgical hand-held instruments and retractor systems, sterile disposable surgical products and sterilization containers. These products are typically used in the surgical specialties of spine, general/OB-GYN, microsurgery/neurosurgery, orthopedics, laparoscopy, cardiovascular, thoracic and general surgery.

The surgical instruments line will be combined with Symmetry's hospital direct business, Specialty Surgical Instrumentation. The combined business will be re-named Symmetry Surgical and based in Nashville, TN.

"The acquisition achieves several strategic objectives for Symmetry, including diversification of our revenue base with higher margin, intellectual property-backed products that generate strong cash flow," Thomas Sullivan, president and CEO of Symmetry Medical, said in a statement. "The acquired assets include a strategic capability in instrument procurement and add scale and a robust international presence to our hospital direct business. When combined with SSi as Symmetry Surgical, they will allow us to expand our global geographic footprint with products that are complementary to our core OEM supplier business."

The transaction is expected to close by the end of the year, subject to customary closing conditions and any necessary government approvals.

- see the Symmetry statement

Read more about: Johnson & Johnson, medical device mergers & acquisitions, Symmetry Medical, Codman & Shurtleff
back to top


2. STERIS, Toshiba team up on hybrid suites

By Liz Jones Hollis Comment | Forward | Twitter | Facebook | LinkedIn

STERIS ($STE) and Toshiba America Medical Systems are teaming up to develop advanced vascular, cardiovascular, pediatric and neurosurgical hybrid surgical suites.

Under the collaboration, Toshiba will provide tableside digital information and imaging technologies, and STERIS will deliver custom-designed high-definition integrated surgical suites featuring LED surgical lighting and visualization systems, and Harmony iQ advanced integration and OR equipment management solutions.

"Hybrid operating rooms offer tremendous opportunities to advance care, but designing and building these complex rooms is a huge task," explained Robert Popilock, senior market development manager, STERIS Surgical Solutions. "Challenges such as how to eliminate collision points for equipment, optimize circulator pathways and provide ergonomic and intuitive tools at the surgical field, must be addressed. We are pleased to be able to help streamline the decision, design and integration processes for customers through collaboration with Toshiba America Medical Systems, a leader in the hybrid OR space."

Hybrid suites have been in the news lately. Recently, Maquet, a unit of Sweden's Getinge Group, discussed its restructuring plans for its U.S. sales and services organization to meet the needs of hybrid operating rooms. Hybrid ORs combine minimally invasive cardiac surgery with percutaneous coronary interventions, eliminating the need to move a patient to a different room, according to the statement.

- see the STERIS release
- check out the Maquet release

Read more about: Steris, Toshiba, Maquet Cardiovascular
back to top


3. Tissue Regenix to raise $39M

By Liz Jones Hollis Comment | Forward | Twitter | Facebook | LinkedIn

Tissue Regenix will raise £25 million ($39 million) through a share placing, leading to the potential creation of 30 jobs in the U.K.

Tissue Regenix was incorporated in May 2006 to commercialize the research of University of Leeds professors Eileen Ingham and John Fisher in the field of tissue decellularization. Its dCELL technology comprises a process that removes cells and other components from human and animal tissue, allowing it to be used to replace worn out or diseased body parts.

The company is looking at sites in York and Leeds for expansion, managing director Antony Odell told The Press. Within the next 6 months or so, the company hopes to identify the site. 

"We have been looking for a while, because we have to look at the further expansion of the company and make sure any site suits us for the future," Odell said, as quoted by the paper.

Tissue Regenix Chairman John Samuel said the money will allow the company "to develop a range of products simultaneously following the established medical device regulatory route, [and] this commitment from both existing and new investors is a significant endorsement of the commercial potential of our broad product pipeline," according to the Post.

- get more from the Yorkshire Post
- check out the story from The Press

Read more about: Tissue Regenix
back to top


4. Bluegrass sees enrollment in Surfacer trial

By Liz Jones Hollis Comment | Forward | Twitter | Facebook | LinkedIn

Patient enrollment has begun in Bluegrass Vascular Technologies' study of its Surfacer inside-out access catheter system. The study will evaluate the safety and effectiveness of the Surfacer in up to 10 patients with upper extremity venous occlusion.

The Surfacer is designed to provide an option for patients with upper extremity venous occlusions that make veins impenetrable by a guide wire or standard access techniques. Using the system, physicians insert a guide wire through the femoral vein in the groin area and navigate up through the torso with an exit point in either the jugular or subclavian vein using fluoroscopy. Bluegrass estimates that more than 3 million patients require central venous access for medical treatment in the U.S. alone.

"The commencement of our first clinical study of the Surfacer is a significant achievement that moves us closer to our goal of offering physicians and their patients game-changing technologies that save veins and save lives," said James Clifton, president of Bluegrass Vascular Technologies. "We are thrilled to be under way with this important research and look forward to announcing the study findings in 2012."

Bluegrass is a spinoff of Therix Medical, which was founded in late 2007 to capitalize on the opportunity to commercialize product concepts from clinicians at the University of Kentucky and other regional medical centers.

- see the Bluegrass release

Related Article:
Therix Medical spins off vascular access company

Read more about: Bluegrass Vascular Technologies
back to top


5. Stryker to shut Gaymar facilities, cut 160 jobs

By Liz Jones Hollis Comment | Forward | Twitter | Facebook | LinkedIn

Gaymar Industries, a manufacturer of support surface and pressure ulcer management solutions, will see its Orchard Park and West Seneca, NY, operations close by the end of 2012, a move that will cost 160 jobs. Gaymar was bought by Stryker ($SYKlast year for $150 million in an all-cash transaction.

A Puerto Rican facility is "not impacted at this time," Stryker said, according to The Buffalo News. Gaymar's equipment will be moved to other Stryker sites and supply chain partners, but the parent company didn't specify where.

The announcement of the closures comes roughly a month after Kalamazoo, MI-based Stryker said it will cut roughly 5% of its workforce and institute other restructuring activities to reduce pretax operating costs by more than $100 million beginning in 2013. The company cited the implementation of the medical device excise tax and a slowdown in elective procedures as reasons for the layoffs.

Gaymar was founded in 1956 and had been owned by private equity firms Nautic Partners and Norwest Equity Partners prior to its acquisition by Stryker. Gaymar and Stryker had been in a 10-year original equipment manufacturer relationship prior to the buyout. The arrangement had given Stryker exclusive rights to sell support surface and pressure ulcer management products to acute care customers in North America.

- get more from The Buffalo News

Related Articles:
Stryker to cut 5% of workforce
Stryker to cut 142 jobs in Ireland

Read more about: Stryker, medical device layoffs, Gaymar Industries
back to top


Also Noted

TODAY'S SPOTLIGHT... Boston Sci introduces Charger catheter

Boston Scientific ($BSX) has launched its Charger PTA balloon catheter for a range of peripheral angioplasty procedures. Charger is the company's third new peripheral balloon catheter introduced in this year. "The Charger PTA Balloon Catheter is designed to deliver results in both routine and challenging cases," said Jeff Mirviss, president of the company's peripheral interventions division. "With a low profile and tapered tip, it is engineered to provide excellent push without sacrificing track. The Charger PTA Balloon Catheter complements our growing portfolio of interventional devices for peripheral vasculature procedures." Boston Scientific release 

> Boston Scientific ($BSX) plans to fight an IRS notice that says the company owes an additional $581 million in taxes, plus interest and penalties. Report

> Ex-Olympus CEO Michael Woodford will meet with lawmakers in Tokyo to lobby for reforms to Japanese boardrooms. The camera and endoscope maker has been embroiled in one of Japan's worst accounting frauds. News

> MELA Sciences ($MELA) has named several new directors to serve on its board--Robert Coradini, Mark Fabiani, John Goddard, James Noble and David Stone. MELA release

> Zimmer Holdings ($ZMH) has announced the availability of its CLS Brevius hip stem with Kinectiv technology in the U.S. that enables surgeons to better match patients' individual anatomies with modular neck options designed for independent, intraoperative adjustments. Zimmer release

> Soteira has received the 510(k) clearance of the Shield kyphoplasty system. "With the addition of the Shield to the existing Soteira portfolio and an active short-cycle pipeline, we are continuing to work toward offering the most comprehensive product portfolio for VCF treatment in the global market," President and CEO Larry Jasinski explained. Soteira statement

And Finally... Mark Cain, CTO of MIM Software, was invited onstage at Apple's Worldwide Developer Conference in 2008 to promote his company's iPhone app, a way for doctors to view incredibly detailed scans of their patients. However, two months after the demo, the FDA told MIM Software to remove the app from Apple's store, saying it needed to be cleared. Now Cain is seeing a lot of apps being bought and sold without FDA supervision. Report

Webinars

> Drug Development: An Overview of the Regulated Clinical Trials Process Used to Bring a New Drug to Market - Dec 13, 1 pm ET/10 am PT

Join us for a one-hour overview of the regulated clinical trials process used to bring a new drug to market. Topics include: Clinical Trial Considerations, Phase 1, Phase 2a and 2b, Phase 3 and 3b, Phase 4, Pharmacoeconomics, Risk Management Plan and more. Register today.

Events

> ExL Pharma's Digital Marketing for Medical Devices: Europe - 12-13 December 2011 - Kempinski Bristol ~ Berlin, Germany

Join us at the first event of its kind for the European Medical Device Industry! In August ExL held the inaugural Digital Marketing for Medical Devices and the event was such a huge hit that it made perfect sense to bring the event to the EU. For the first time ever device marketers in Europe will have their very own conference to explore the most cutting edge topics and network with their peers. Featuring key sessions from: Medtronic, Zimmer, Biotronik, B.Braun Melsungen AG, Bausch + Lomb, Smiths Medical, Sharp & Dohme GMBH and many more! For more info click here. Save 10% off standard registration rates. Use discount code:C113FMD

> Online GMP Courses Priced as Low as $75 for Individual Learners

Our web-based GMP courses can be purchased online and taken at your own pace. Once completed with adequate proficiency, you'll receive a certificate of completion. Developed by GMP experts and taken by thousands, these courses provide quality GMP training for far less than other alternatives. Click Here

Marketplace

> Digital Health Technology: A Guide to Medtech's Biggest New Player

Are you up to date on the latest in digital health technology? Let Elsevier Business Intelligence guide you in navigating this growing field. This report covers new technology and policies that could affect your bottom line. Learn more at http://pages.elsevierbi.net/digitalhealth/

Jobs

> Director, Reagent Manufacturing & Operations - San Francisco, CA - Fluidigm

Directly reporting to the VP of Manufacturing, the Director will be responsible for managing and directing Fluidigm's Reagents and Assays Manufacturing operations. This includes formulating manufacturing operations strategies in support of business goals and objectives, developing and mentoring manufacturing employees and driving continuous improvements to achieve optimal operational efficiency. He or she will set up the systems and tools to deliver quality products and services that will meet customers' expectations in the most cost-effective manner. The Director will also lead and manage the supply chain operations in South San Francisco which includes but is not limited to: purchasing, inventory management, supplier management... Learn more.

 

> Director of Operations at Pharm-Olam International

Opportunity for Director of Operations, with a dynamic and growing international Contract Research Organization ("CRO"), based at our global headquarters in Houston, TX. Director will assist the executive team in developing strategic and operational initiatives and their implementation. The successful candidate will provide leadership and direction to multiple departments in various countries to continue improving efficiency, improving processes and achieving corporate goals. Must have the energy and desire to help develop the best company in its field. Learn more here.

> Manager, Strategic Forecasting & Analytics Job – NJ – Celgene Corporation

Celgene Corporation is a global biopharmaceutical company that is helping to turn incurable cancers into chronic, manageable conditions. An ideal candidate for this position will have BS/BA degree. The Manager, Strategic Forecasting & Analytics will provide ongoing forecasting and long-range analytical support for the Americas Hematology/Oncology business. The Manager will participate on cross-functional teams including marketing, market research, new product planning, sales operations, business development, manufacturing, finance, and strategic planning....Learn more.

> Sr. Product Manager – NJ – Celgene Corporation

Celgene Corporation is a global biopharmaceutical company that is helping to turn incurable cancers into chronic, manageable conditions. An ideal candidate for this position will have BS/BA degree and a minimum of 7 years' pharma/biotech industry and 3 years product management/marketing research. Sales experience in the pharmaceutical industry required. The Sr. Product Manager assists in the development and implementation of marketing and educational programs, leading segments of the projects as appropriate. Also participates in the development of business plans, product strategies, and tactical implementation.....Learn more.

> Business Analyst - Gaithersburg, MD - MedImmune

MedImmune is a company that shares your passion for helping to improve human health around the world. Explore a MedImmune career as we strive to better more lives, more often, around the world. The Business Analyst works as a liaison among stakeholders in order to elicit, analyze, communicate, and validate requirements for changes to business processes and information systems. The role is responsible for understanding and documenting business requirements for specific business problems, translating business requirements into functional specifications, and verifying that solutions meet the requirements...Read more.

> IT Infrastructure Portfolio & Planning Analyst - Gaithersburg, MD - MedImmune

MedImmune is a company that shares your passion for helping to improve human health around the world. Explore a MedImmune career as we strive to better more lives, more often, around the world. The Senior Analyst, IT Infrastructure Portfolio & Planning is responsible for the planning, management, and execution of capacity planning, forecasting, and requirements definition for all IT infrastructure domains including LANs, WANs, servers, storage, telephony, etc. Candidates should have at least five (5) years of experience in the area of analytic and/or discrete event simulation modeling...Read more.

 

> Senior Manager, Information Architect - Gaithersburg, MD - MedImmune

MedImmune is a company that shares your passion for helping to improve human health around the world. Explore a MedImmune career as we strive to better more lives, more often, around the world. This position requires at least 8+ years of work experience in an Information Systems and 5+ years of experience in Information management functions. Responsibilities include developing and evangelizing Enterprise Information Architecture and providing leadership for developing and maintaining the Enterprise Information Architecture...Read more.

> Systems Analyst - Gaithersburg, MD - MedImmune

MedImmune is a company that shares your passion for helping to improve human health around the world. Explore a MedImmune career as we strive to better more lives, more often, around the world. The Systems Analyst enables the technical delivery of projects with adherence to defined technical standards and provides support for domain and enterprise applications. This position requires 3 or more years of relevant work experience including business analysis, testing / quality assurance, Application Development and Operations...Read more.

> Data Center Fac.Engineer– Gaithersburg, MD - MedImmune

MedImmune is a company that shares your passion for helping to improve human health around the world. Explore a MedImmune career as we strive to better more lives, more often, around the world. The Data Center Facilities Engineer will support MedImmune, Inc. data centers (DC), main distribution frames (MDF), intermediate distribution frame (IDF), throughout MedImmune, Inc. Global Sites. This position requires 5 or more years of experience in an industrial setting. (DATA Center or Critical Environment experience Preferred)...Read more.


©2011 FierceMarkets This email was sent to nbrauchitsch@yahoo.com as part of the FierceMedicalDevices email list which is administered by FierceMarkets, 1900 L Street NW, Suite 400, Washington, DC 20036, (202) 628-8778. Refer FierceMedicalDevices to a Colleague

Contact Us

Editor: Elizabeth Jones. Executive Editor: Ryan McBride. Managing Editor: Maureen Martino. Publisher: Arsalan Arif. VP, Sales: Ryan Willumson.

Advertise

Advertising/Lead-Generation: Ryan Willumson. Request a media kit.

Email Management

Manage your subscription

Change your email address

Unsubscribe from FierceMedicalDevices

Explore Our Network

You may enjoy these publications from FierceMarkets:

Friday, April 15, 2011

Services

New Twitter
App Gets You Free Traffic.. Click Here To See How >>

Services



Custom Search

Monday, December 27, 2010